Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( (THAR) ) has provided an announcement.

Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral version of the anti-inflammatory drug infliximab, expanding its immunology pipeline. The deal gives Tharimmune global rights to Intract’s advanced delivery platforms, Soteria® and Phloral®, and includes potential milestone payments, royalties, and options for additional targets. This oral formulation could revolutionize treatment by improving patient compliance and reducing healthcare burdens associated with intravenous infusions.

For an in-depth examination of THAR stock, go to TipRanks’ Stock Analysis page.